The Wegovy Tablet: What It Is, How You Take It, and What to Expect

Step 1: Understanding what the Wegovy tablet actually is

There is a common assumption that a tablet version of a GLP-1 medicine would simply be a capsule version of the injection, absorbed in the usual way. It isn't quite that straightforward. Semaglutide is a large protein molecule that the gut would normally break down before it reaches the bloodstream. The Wegovy tablet gets around this by combining semaglutide with sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, or SNAC, an absorption enhancer that allows the semaglutide to pass through the stomach lining directly into circulation. The result is a genuine once-daily oral medicine, not a workaround. You can read more about how semaglutide works across its different forms on our Wegovy pill overview page.

Novo Nordisk developed the tablet under the Wegovy brand, and the MHRA's approval on 11 June 2026 made the UK the first country in Europe to licence it for weight management. It is approved for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. That eligibility mirrors the injection's licensed criteria fairly closely, though clinical suitability is always decided by a prescriber, not a checklist.

One thing worth knowing from the start: semaglutide tablets already exist under a different brand name, Rybelsus, but those are licensed for type 2 diabetes at much lower doses. Rybelsus and the Wegovy weight-loss tablet are entirely separate products with separate dose ladders. The 3mg, 7mg and 14mg tablet strengths belong to Rybelsus. If you want a clear breakdown of how Wegovy tablets differ from other semaglutide products, including the dose ladders that set them apart, our dedicated page covers this in full. The Wegovy weight-loss schedule is 1.5mg, 4mg, 9mg and 25mg.

Step 2: Taking the tablet correctly — the routine that makes it work

The absorption mechanism that makes the Wegovy tablet possible also makes the taking instructions more specific than most once-daily medicines. The tablet is taken first thing in the morning, before any food, drink or other oral medicines. You swallow it whole with a small amount of plain water, roughly up to 120ml. After that, you wait at least 30 minutes before eating, drinking anything else (coffee included) or taking other medicines.

That waiting window exists because food, hot drinks and other substances in the stomach can interfere with SNAC's absorption-enhancing effect. Missing the window occasionally is unlikely to be catastrophic, but making it a reliable habit is genuinely important for getting the most from treatment. Many people find it easiest to take the tablet the moment they wake, before the morning routine begins.

Storage is considerably simpler than the injection. The tablet needs no refrigeration at all, which means it travels well and doesn't require the same planning that a fridge-dependent pen demands. If you are weighing up your options, our page on Wegovy oral tablets explains why some patients find this format suits their lifestyle better than the injection, particularly those who travel frequently or who have strong reservations about self-injecting.

For the precise storage conditions, permitted temperature range and full administration detail, the patient information leaflet and the Wegovy tablet Summary of Product Characteristics on the Electronic Medicines Compendium are the definitive references.

Step 3: The dose escalation schedule and what trial evidence shows

Treatment starts at 1.5mg daily. After at least one month, the prescriber moves to 4mg, then 9mg, then the 25mg maintenance dose, with a minimum of one month at each stage. The gradual escalation exists for the same reason as the injection's titration: it gives the body time to adjust and reduces the likelihood of gastrointestinal side effects, which are more noticeable at the start of treatment and after each increase.

The pivotal trial for the Wegovy weight-loss tablet was OASIS 4, a phase 3 study of 307 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes, over 64 weeks. Participants achieved an average weight loss of around 13.6% compared with roughly 2.4% on placebo, alongside lifestyle changes. Among those who stayed fully adherent to treatment throughout, the figure rose to around 17%. That distinction matters: 17% reflects best-case adherence in a controlled trial; 13.6% is the broader average. Both are from the MHRA approval announcement and Novo Nordisk's UK approval communications.

The most common side effects in OASIS 4 were gastrointestinal: nausea, vomiting, diarrhoea and constipation featured in roughly three-quarters of participants taking the active medicine, compared with just over four in ten on placebo. They were mostly mild to moderate and tended to settle as the body adjusted, particularly after the dose-increase phase passed. Our page on Wegovy tablet form goes into more detail on what to expect as you move through the dose escalation stages, and the NHS semaglutide medicines page covers the semaglutide safety profile clearly.

Access, NHS status, and taking the next step

The Wegovy tablet is currently available on a private prescription only. A NICE appraisal would be needed before it could be commissioned on the NHS, and that process takes time. For people who don't want to wait, a regulated private service is the route. You can find an overview of the private treatment options available at nume on the weight-loss treatments page, where current pricing is also shown.

Every prescription through nume is reviewed personally by a GPhC-registered Independent Prescriber, on the same day you submit your consultation. There are no algorithms making clinical decisions. Identity and weight are verified, your medical history is assessed, and if treatment is clinically suitable, it is dispensed from our GPhC-registered pharmacy and dispatched the same day for free next-working-day delivery.

Before starting any GLP-1 medicine, it is worth reviewing the frequently asked questions on our site, and reading up on what the treatment involves. The Wegovy tablet is a genuinely new option for people who are suited to it. Whether it's the right choice for you is a clinical question. Our prescribers are here to help you think it through.